Other variants, such as those in HSD17B13 and MAMSTR, were found to have larger effects on cirrhosis compared with NAFLD, indicating a more dominant role in the progression to clinically advanced stages of chronic liver disease. Here, MAMSTR is linked to metabolic dysfunction-associated steatotic liver disease.